ZEB1 and hepatocellular carcinoma: Instead, 25.5–48.7% of total csMVP-positive CTCs are positive for the expression of vimentin, Slug, or ZEB1 in HCC patients (Table 2), indicating that a substantial number of the csMVP-positive CTCs have mesenchymal phenotype.